RECRUITING

BRInging the Diabetes Prevention Program to GEriatric Populations

Description

Over 24 million Americans are over 65 years and have prediabetes. Prediabetes can be addressed using a public health approach: among the 20% of participants in the Diabetes Prevention Program (DPP) who were ages 60 and over, the diet and physical activity intervention conferred a 71% risk reduction of diabetes after an average follow-up of 3 years. The population of older adults is projected to more than double from 52.5 million in 2019 to \~100 million by 2060, and if projections hold, about half (48.3%) will have prediabetes. The proposed hybrid effectiveness implementation type 1 design will compare a DPP program Tailored for Older Adults and delivered via Telehealth (DPP-TOAT arm) to an in person DPP tailored for older adults (DPP arm) using a randomized, controlled trial design (n=230). The preliminary data suggests DPP-TOAT is a feasible and acceptable way to deliver the DPP to older adults, and this will be the first study to compare the effectiveness and implementation of two strategies (telehealth versus in-person) to deliver a tailored DPP for the unique needs of the growing population of older adults.

Conditions

Study Overview

Study Details

Study overview

Over 24 million Americans are over 65 years and have prediabetes. Prediabetes can be addressed using a public health approach: among the 20% of participants in the Diabetes Prevention Program (DPP) who were ages 60 and over, the diet and physical activity intervention conferred a 71% risk reduction of diabetes after an average follow-up of 3 years. The population of older adults is projected to more than double from 52.5 million in 2019 to \~100 million by 2060, and if projections hold, about half (48.3%) will have prediabetes. The proposed hybrid effectiveness implementation type 1 design will compare a DPP program Tailored for Older Adults and delivered via Telehealth (DPP-TOAT arm) to an in person DPP tailored for older adults (DPP arm) using a randomized, controlled trial design (n=230). The preliminary data suggests DPP-TOAT is a feasible and acceptable way to deliver the DPP to older adults, and this will be the first study to compare the effectiveness and implementation of two strategies (telehealth versus in-person) to deliver a tailored DPP for the unique needs of the growing population of older adults.

BRInging the Diabetes Prevention Program to GEriatric Populations

BRInging the Diabetes Prevention Program to GEriatric Populations

Condition
Pre Diabetes
Intervention / Treatment

-

Contacts and Locations

New York

NYU Langone Health, New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Men and women aged 65 years and older
  • * Diagnosis of pre-diabetes (A1c between 5.7-6.4%, fasting glucose between 100-125 mg/dL, or oral glucose tolerance test between 140-199 mg/dL within past 12 months)
  • * BMI of greater than or equal to 30
  • * English-speaking
  • * Under the care of a Primary care provider (PCP) in the NYU Langone Health system
  • * Able to travel to NYU Langone for in-person evaluations
  • * Access to a telephone
  • * Informed consent
  • * Prevalent diabetes or end-stage renal disease
  • * Prior participation in the Diabetes Prevention Program
  • * A documented current history of active psychosis or other cognitive issues via International Classification of Diseases (ICD) -10 codes
  • * Taking FDA-approved weight loss medications
  • * PCP stating that patient should not participate
  • * Inability to communicate due to severe, uncorrectable hearing loss or speech disorder
  • * Severe visual impairment that precludes completion of assessments and/or intervention

Ages Eligible for Study

65 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

NYU Langone Health,

Jeannette M Beasley, PhD, RDN, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Joshua Chodosh, MD, MHS, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

2026-11